Telix Pharmaceuticals is trading 5.5% down at $11.14 following several ASX filings that have prompted investor repositioning ahead of the U.S. session.
- The company lodged notifications regarding the cessation of securities and unquoted securities on July 10, 2026.
- An application for the quotation of additional securities was also filed, contributing to the downward price action in pre-market trading.